MIRAE ASSET
HEALTHCARE FUND - (MAHCF)

(Sectoral/Thematic Fund - An open ended equity scheme investing in healthcare and allied sectors)
Details as on November 30, 2022
Type of Scheme Sectoral/Thematic Fund - An open ended equity scheme investing in healthcare and allied sectors
Investment Objective The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns.
Fund Manager**
Mr. Vrijesh Kasera
(since July 02, 2018)
Allotment Date 02nd July, 2018
Benchmark Index S&P BSE Healthcare Index (TRI)
Minimum Investment
Amount
₹ 5,000/- and in multiples of ₹ 1/-thereafter. Minimum Additional Application Amount: ₹ 1,000/- per application and in multiples of ₹ 1/- thereafter.
Systematic Investment
Plan (SIP)
(Any Date SIP is available from 1st July, 2019)
Monthly and Quarterly: ₹ 1,000/- (multiples of ₹ 1/- thereafter), minimum 5 in case of Monthly or 3 in case of Quarterly option.
Load Structure Entry load: NA
Exit load:
I. For investors who have opted for SWP under the plan:
a) 15% of the units allotted (including Switch-in/STP - in) on or before completion of 365 days from the date of allotment of units: Nil.
b) Any redemption in excess of such limits in the first 365 days from the date of allotment shall be subject to the following exit load: (Redemption of units would be done on First In First Out Basis (FIFO):
•If redeemed within 1 year (365 days) from the date of allotment: 1%
•If redeemed after 1 year (365 days) from the date of allotment: NIL
II. Other Redemptions: For Investors who have not opted for SWP under the plan (including Switch out, STP out):
•If redeemed within 1 year (365 days) from the date of allotment: 1%
•If redeemed after 1 year (365 days) from the date of allotment: NIL
Plans Available Regular Plan and Direct Plan
Options Available Growth Option and IDCW^ Option (Payout & Re-investment)
Monthly Average AUM
(₹ Cr.) as on November 30, 2022
1,725.48
Net AUM (₹ Cr.) 1,724.64
Monthly Avg. Expense Ratio
(Including Statutory Levies)
as on November 30, 2022
Regular Plan: 2.07%
Direct Plan: 0.50%
**For experience of Fund Managers Click Here
^Pursuant to Notice cum addendum dated March 27, 2021 the nomenclature of dividend option has been changed w.e.f. April 01, 2021.
NAV: Direct Regular
Growth ₹ 23.729 ₹ 22.128
IDCW^ ₹ 19.988 ₹ 18.518
Volatility 21.27%
Beta: 0.93
R Squared 0.97
Sharpe Ratio#: 0.97
Information Ratio 1.34
Portfolio Turnover Ratio 0.21 times

@The Volatility, Beta, R Squared, Sharpe Ratio & Information Ratio are calculated on returns from last three years Monthly data points. # Risk free rate: FBIL OVERNIGHT MIBOR as on 30th November, 2022.^Basis last rolling 12 months.

Record Date IDCW (₹) Face Value ( ₹) Cum Nav ( ₹)
22-Mar-22
1.80 per Unit
10
22.196
27-Oct-22
1.80 per Unit
10
20.139

Past Performance may or may not be sustained in future. Pursuant to payment of IDCW the NAV of the IDCW option of the scheme will fall to the extent of payout and statutory levy (if any). IDCW history is for MAHCF - Regular Plan - IDCW Option

Portfolio Holdings % Allocation
Pharmaceuticals & Biotechnology
Sun Pharmaceutical Industries Ltd
18.29%
Cipla Ltd
10.07%
Dr. Reddy's Laboratories Ltd
7.32%
Torrent Pharmaceuticals Ltd
6.07%
JB Chemicals & Pharmaceuticals Ltd
5.12%
Aurobindo Pharma Ltd
3.72%
Ajanta Pharma Ltd
3.63%
IPCA Laboratories Ltd
3.13%
Divi's Laboratories Ltd
2.94%
Alkem Laboratories Ltd
2.68%
Gland Pharma Ltd
2.65%
Laurus Labs Ltd
2.40%
Biocon Ltd
2.16%
Lupin Ltd
2.04%
Natco Pharma Ltd
1.11%
Abbott India Ltd
0.00%
Sanofi India Ltd
0.00%
Healthcare Services
Apollo Hospitals Enterprise Ltd
7.94%
Krishna Institute Of Medical Sciences Ltd
5.51%
Fortis Healthcare Ltd
2.93%
Dr. Lal Path Labs Ltd
0.41%
Syngene International Ltd
0.11%
Insurance
SBI Life Insurance Company Ltd
1.53%
ICICI Lombard General Insurance Company Ltd
1.50%
Max Financial Services Ltd
1.24%
Chemicals & Petrochemicals
Vinati Organics Ltd
2.05%
Tatva Chintan Pharma Chem Ltd
1.88%
Healthcare Equipment & Supplies
Tarsons Products Ltd
1.45%
Equity Holding Total
99.88%
Cash & Other Receivables
0.12%
Total
100.00%

Positions Increased
Stock
Healthcare Services
Apollo Hospitals Enterprise Limited
Pharmaceuticals & Biotechnology
Aurobindo Pharma Limited
Biocon Limited
Cipla Limited
Dr. Reddy's Laboratories Limited
Gland Pharma Limited
Positions Decreased
Stock
Healthcare Services
Krishna Institute Of Medical Sciences Limited
Insurance
SBI Life Insurance Company Limited
Chemicals & Petrochemicals
Vinati Organics Limited
Pharmaceuticals & Biotechnology
Divi's Laboratories Limited
IPCA Laboratories Limited
JB Chemicals & Pharmaceuticals Limited
Laurus Labs Limited
Lupin Limited
Sun Pharmaceutical Industries Limited

Growth of Rs. 10,000 invested at inception: 22,128

Returns (in%)
Returns (in%)
1 Yr 3 Yrs SI
MAHCF
-4.84%
26.45%
19.70%
Scheme Benchmark*
-5.45%
21.49%
13.82%
Additional Benchmark**
12.04%
16.98%
15.44%
NAV as on 30th November, 2022 ₹ 22.128
Index Value (30th November, 2022) Index Value of Scheme benchmark is 27,273.58 and S&P BSE Sensex (TRI) is 95,383.95
Allotment Date 02nd July, 2018
Scheme Benchmark *S&P BSE Healthcare Index (TRI)
Additional Benchmark **S&P BSE Sensex (TRI)

Fund manager : Mr. Vrijesh Kasera managing the scheme since July 02, 2018
Note: Returns below or for 1 year are absolute returns, returns above 1 year are CAGR- Compounded Annualized Growth returns.

Period Total Amount Invested Mkt Value as on
30-November-2022
SI
520,000
793,370
3 Yr
360,000
452,236
1 Yr
120,000
121,160

Returns (%)
Period
SI
3yr
1yr
Fund Return& (%)
19.73
15.41
1.80
Benchmark Return& (%)
15.07
12.76
2.82
Add. Benchmark Return& (%)
18.76
22.06
20.35

& The SIP returns are calculated by XIRR approach assuming investment of ₹ 10,000/- on the 1st working day of every month.

This product is suitable for investors who are seeking*
• To generate long term capital appreciation
• Investments in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sector in India

*Investors should consult their financial advisers if they are not clear about the suitability of the product.


Past Performance may or may not be sustained in future. Note : For computation of since inception returns (%) the allotment NAV has been taken as ₹ 10.00. The performance of other funds managed by the same fund manager is given in the respective page of the schemes
Different Plans under the scheme has different expense structure. The reference and details provided here in are of Regular Plan - Growth Option